Top Tweets for #CompleteResponse

18 days ago

#1AD #FDA #CarT #Cancer #CompleteResponse #BIOTECH 🔥AdAlta engages sector-leading advisors to support US FDA engagement for BZDS1901 CAR-T therapy 📢BZDS1901 has delivered multiple tumour responses (shrinkage) in patients with advanced and refractory mesothelioma, including two patients who have achieved complete tumour clearance (COMPLETE RESPONSE) that remain ongoing at 6 and 22 months after treatment respectively BZDS1901 targets an estimated US$4.2 billion segment of the advanced mesothelioma market ⚡️AdAlta has engaged Dark Horse Consulting Group, Inc (“DHC”), a leading specialist in cell and gene therapy development, to support regulatory engagement with US Food and Drug Administration (“FDA”) for its BZDS1901 CAR-T therapy ⚡️focus on preparing for a near-term pre-IND meeting with the FDA ⚡️potential advanced regulatory designations and accelerated pathways

$MrShare_expert's tweet photo. #1AD #FDA #CarT #Cancer #CompleteResponse #BIOTECH 🔥AdAlta engages sector-leading advisors to support US FDA engagement for BZDS1901 CAR-T therapy 📢BZDS1901 has delivered multiple tumour responses (shrinkage) in patients with advanced and refractory mesothelioma, including two patients who have achieved complete tumour clearance (COMPLETE RESPONSE) that remain ongoing at 6 and 22 months after treatment respectively BZDS1901 targets an estimated US$4.2 billion segment of the advanced mesothelioma market ⚡️AdAlta has engaged Dark Horse Consulting Group, Inc (“DHC”), a leading specialist in cell and gene therapy development, to support regulatory engagement with US Food and Drug Administration (“FDA”) for its BZDS1901 CAR-T therapy ⚡️focus on preparing for a near-term pre-IND meeting with the FDA ⚡️potential advanced regulatory designations and accelerated pathways$

AlphaBronze

@Alpha_Bronze

11 months ago

FDA Publishes Cache of Complete Response Letters in Bid for ‘Radical Transparency’! #healthcare #CompleteResponse #FDA https://t.co/SItx1Gsqpj

VJHemOnc

@VJHemOnc

12 months ago

Pre-transplant CR in HR-MDS: insights from @MaxStahlMD @VJHemOnc #iwMDS25 #iwMPN25 #BMT #CompleteResponse

534

ipharmacenter @ipharmacenter

over 2 years ago

KEYNOTE-671 trial had previously achieved the other primary endpoint of event-free survival (EFS) during its first interim analysis, and pathological #completeresponse (pCR) and major #pathologicalresponse (mPR) https://t.co/wpy6ItUDPa #news #media #ESMO23 #ESMO2023 #Science

395

Vishal Navani, MD @navstruck

about 3 years ago

So happy to work with the excellent @DrTakemura & @DrDanielHeng about the contemporary implications of #completeresponse in #kidneycancer Thanks to @IMDConline collaborators @montypal @tompowles1 @neerajaiims

Kosuke Takemura @DrTakemura

about 3 years ago

Our paper is out @JUrology Real-world evidence of complete response to first-line therapies #kidneycancer Many thanks to the IMDC collaborators!! @DrDanielHeng @DrChoueiri @IMDConline

Cellectar Biosciences @CellectarBio

over 3 years ago

Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient https://t.co/JSlAz0rQ1m #clinicaltrials #clinicalresearch #Lyphoma #CompleteResponse #bloodcancer #RareDiseaseDay2023 $CLRB

$CellectarBio's tweet photo. Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient https://t.co/JSlAz0rQ1m #clinicaltrials #clinicalresearch #Lyphoma #CompleteResponse #bloodcancer #RareDiseaseDay2023 $CLRB https://t.co/zdUPX7bWcf$

166

Hegel Hernandez @Hegel_MD_PhD

almost 4 years ago

🚨@oncoalert @NEJM #dostarlimab 👏ALL 12 pts (100%) w/MMRD stage II or III #rectaladeno treated w/neoadj #dostarlimab had clinical #completeresponse ✅No evidence of tumor on MRI, 18F-FDG–PET, endoscopic, digital rectal examination, or biopsy Check👇 https://t.co/3QYseIa222

Hegel_MD_PhD's tweet photo. 🚨@oncoalert @NEJM #dostarlimab

👏ALL 12 pts (100%) w/MMRD stage II or III #rectaladeno treated w/neoadj #dostarlimab had clinical #completeresponse

✅No evidence of tumor on MRI, 18F-FDG–PET, endoscopic, digital rectal examination, or biopsy

Check👇
https://t.co/3QYseIa222 https://t.co/1QTyDsecwn

Gregg Nelson @GreggNelsonERAS

about 4 years ago

Incredible opportunity to hear @AndreaCercek speak about #PD1 #blockade in #mismatch #repairdeficient locally advanced #rectalcancer at #SocietyofPelvicSurgeons @MSKCancerCenter 100% #completeresponse 👏 🎉 @NEJM @ASCO https://t.co/PLefyhFtSy

GreggNelsonERAS's tweet photo. Incredible opportunity to hear @AndreaCercek speak about #PD1 #blockade in #mismatch #repairdeficient locally advanced #rectalcancer at #SocietyofPelvicSurgeons @MSKCancerCenter 100% #completeresponse 👏 🎉 @NEJM @ASCO https://t.co/PLefyhFtSy https://t.co/nzZpyPeKkm

Peter C Desmond @PeterCDesmond

over 5 years ago

All set for Nivo #5 treatment, still a complete responder, dietitian just popped in to say she wants a chat, better avoid the digestive biscuit #ipinivo #nivo #cancer #KidneyCancer #KidneyCancerAwareness #completeresponse

PeterCDesmond's tweet photo. All set for Nivo #5 treatment, still a complete responder, dietitian just popped in to say she wants a chat, better avoid the digestive biscuit #ipinivo #nivo #cancer #KidneyCancer #KidneyCancerAwareness #completeresponse https://t.co/nPJQCiH7CU

Dr So Him @sotszhim

over 5 years ago

I am going to present a case in MiniOral session in upcoming #ESMOAsia2020 in #Singapore (virtually). We will present how we successfully used #immunotherapy plus #radiation to treat a refractory metastatic #ProstateCancer and achieve almost #CompleteResponse

$sotszhim's tweet photo. I am going to present a case in MiniOral session in upcoming #ESMOAsia2020 in #Singapore (virtually). We will present how we successfully used #immunotherapy plus #radiation to treat a refractory metastatic #ProstateCancer and achieve almost #CompleteResponse https://t.co/BdhMP1EAOt$

Matt Lee @wannabehawkeye

almost 6 years ago

Fab keynote on #completeresponse to wrap up #DukesVirtualWeek . Fascinating

Karol Polom @polom_karol

over 6 years ago · Gdynia

#teamwork #Eysac #collaboration #colorectalcancer #colorectalsurgery #completeresponse

European Journal of Surgical Oncology @ejsotweets

over 6 years ago

GLOBAL VARIATION IN THE LONG-TERM OUTCOMES OF ypT0 RECTAL CANCERS @LauraLorenzonMD @MDAnderson_ES @tiborkovacsdr @polom_karol #CORSICA #EYSAC https://t.co/dSVwk7GT8G @ESSOnews @OncologyAdvance @escp_tweets @SocSurgOnc @myesmo @ESTRO_RT @ASiTofficial @SAGES_Updates @ASCRS_1

ejsotweets's tweet photo. GLOBAL VARIATION IN THE LONG-TERM OUTCOMES OF ypT0 RECTAL CANCERS

@LauraLorenzonMD @MDAnderson_ES @tiborkovacsdr @polom_karol #CORSICA #EYSAC

https://t.co/dSVwk7GT8G

@ESSOnews @OncologyAdvance @escp_tweets @SocSurgOnc @myesmo @ESTRO_RT @ASiTofficial @SAGES_Updates @ASCRS_1 https://t.co/JfD3AqLNRz

Karol Polom @polom_karol

over 6 years ago · Republic of Slovenia

The last day of #colorectalsurgery #handson course by @ESSOnews we start with an excellent presentation 🇳🇱 experience by #hillingdenise @UniLeiden #completeresponse #cCR #pCR #colorectalcancer

polom_karol's tweet photo. The last day of #colorectalsurgery #handson course by @ESSOnews we start with an excellent presentation 🇳🇱 experience by #hillingdenise @UniLeiden #completeresponse #cCR #pCR #colorectalcancer https://t.co/ZsiohUCQmp

Omid Hamid MD

@OmidHamidMD

over 6 years ago

The real meat here is the CR rate. Even if the responses are equal the ability to get to CR on this % is amazing. #CR #completeresponse is the holy grail. #SITC2019 @SITC @angelesclinic

SY Investing @syinvesting

over 6 years ago

Interesting $NKTR Bempeg (NKTR-214) + Nivolumab combo data at #SITC2019 - Ph 1/2 PEG-IL2+PD-1 in 1L metastatic melanoma - ORR: 53% (20/38) - CR: 34% (13/38) - PD-L1- ORR: 39% (5/38) - PD-L1+ ORR: 64% (14/38) - Median time to response: 2.0 mos Deck: https://t.co/Z7s0BFb7cp

syinvesting's tweet photo. Interesting $NKTR Bempeg (NKTR-214) + Nivolumab combo data at #SITC2019

- Ph 1/2 PEG-IL2+PD-1 in 1L metastatic melanoma
- ORR: 53% (20/38)
- CR: 34% (13/38)
- PD-L1- ORR: 39% (5/38)
- PD-L1+ ORR: 64% (14/38)
- Median time to response: 2.0 mos

Deck: https://t.co/Z7s0BFb7cp https://t.co/ek5xrCbbVF

Sidhartha Tavri, MBBS DABR FSIR @SidTavri

almost 7 years ago

Intrigued by @EmbolxInc Sniper. Trying to exploit changes in downstream flow physiology after balloon occlusion. @JVIRmedia @SIRspecialists @SIRRFS @UHRadiology #completeresponse

SidTavri's tweet photo. Intrigued by @EmbolxInc Sniper. Trying to exploit changes in downstream flow physiology after balloon occlusion. @JVIRmedia
@SIRspecialists @SIRRFS @UHRadiology
#completeresponse https://t.co/qjKCwsJNw5

Abhishek Kumar MD FSIR

@AbhiKumar47

over 7 years ago

Childs Pugh A cirrhotic with 5 cm infiltrative hcc with enhancing tumor thrombus in right portal vein. Y90 segmentectomy dose —> nothing but dead tumor at 3 months. #completeresponse #justnukeit #radialfirst #irad @JVIRmedia @BTGIO